KPV + GHK-Cu + TB-500 + BPC-157 — expanded regenerative + anti-inflammatory research stack.
The KLOW Stack extends the Glow protocol with KPV (the C-terminal tripeptide of α-MSH) to introduce melanocortin-mediated anti-inflammatory signaling alongside GHK-Cu, TB-500 and BPC-157 in soft-tissue and mucosal-repair research.
KPV inhibits NF-κB nuclear translocation and pro-inflammatory cytokine release; GHK-Cu drives matrix remodeling; BPC-157 promotes angiogenesis via VEGFR2-Akt-eNOS; TB-500 supports cell migration through actin sequestration. The four peptides span anti-inflammatory, vascular, cytoskeletal and ECM axes of repair.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Oral tripeptide KPV uptake via PepT1 in colonic epithelial and immune cells under DSS-induced colitis.
Reduced inflammation, lower pro-inflammatory cytokine expression and improved colonic histology vs. control.
Synthesis of GHK-Cu's modulation of regenerative pathways across cell types.
Broad activation of repair, ECM-remodeling and antioxidant gene programs.
Review of BPC-157's reproducible mucosal protective effect across independent laboratories.
Consistent acceleration of lesion resolution across cysteamine, ethanol and indomethacin models.
Store lyophilized at -20°C, protected from light. Reconstituted vials: 2–8°C, use within 30 days for research.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — KLOW Stack is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
